These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 29750737)

  • 21. Effects of methylphenidate on body index and physical fitness in Korean children with attention deficit hyperactivity disorder.
    Kang KD; Yun SW; Chung U; Kim TH; Park JH; Park IH; Han DH
    Hum Psychopharmacol; 2016 Mar; 31(2):76-82. PubMed ID: 26756111
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Absence of cytogenetic effects in children and adults with attention-deficit/hyperactivity disorder treated with methylphenidate.
    Ponsa I; Ramos-Quiroga JA; Ribasés M; Bosch R; Bielsa A; Ordeig MT; Morell M; Miró R; de Cid R; Estivill X; Casas M; Bayés M; Cormand B; Hervás A
    Mutat Res; 2009 Jun; 666(1-2):44-9. PubMed ID: 19457516
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ABCB1 c.2677G>T variation is associated with adverse reactions of OROS-methylphenidate in children and adolescents with ADHD.
    Kim SW; Lee JH; Lee SH; Hong HJ; Lee MG; Yook KH
    J Clin Psychopharmacol; 2013 Aug; 33(4):491-8. PubMed ID: 23771192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. OROS methylphenidate for the treatment of adults with attention-deficit/hyperactivity disorder.
    Ramos-Quiroga JA; Corominas M; Castells X; Bosch R; Casas M
    Expert Rev Neurother; 2009 Aug; 9(8):1121-31. PubMed ID: 19673602
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Methylphenidate DAT binding in adolescents with Attention-Deficit/ Hyperactivity Disorder comorbid with Substance Use Disorder--a single photon emission computed tomography with [Tc(99m)]TRODAT-1 study.
    Szobot CM; Shih MC; Schaefer T; Júnior N; Hoexter MQ; Fu YK; Pechansky F; Bressan RA; Rohde LA
    Neuroimage; 2008 Apr; 40(3):1195-201. PubMed ID: 18282769
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects of perinatal methylphenidate (MPH) treatment in male and female Sprague-Dawley offspring.
    Panos JJ; Law CD; Ferguson SA
    Neurotoxicol Teratol; 2014; 42():9-16. PubMed ID: 24444667
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Correlation between methylphenidate and ritalinic acid concentrations in oral fluid and plasma.
    Marchei E; Farré M; Pardo R; Garcia-Algar O; Pellegrini M; Pacifici R; Pichini S
    Clin Chem; 2010 Apr; 56(4):585-92. PubMed ID: 20167695
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Empathy and Facial Expression Recognition in Children With and Without Attention-Deficit/Hyperactivity Disorder: Effects of Stimulant Medication on Empathic Skills in Children with Attention-Deficit/Hyperactivity Disorder.
    Gumustas F; Yilmaz I; Yulaf Y; Gokce S; Sabuncuoglu O
    J Child Adolesc Psychopharmacol; 2017 Jun; 27(5):433-439. PubMed ID: 28332851
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comparative pharmacodynamics and plasma concentrations of d-threo-methylphenidate hydrochloride after single doses of d-threo-methylphenidate hydrochloride and d,l-threo-methylphenidate hydrochloride in a double-blind, placebo-controlled, crossover laboratory school study in children with attention-deficit/hyperactivity disorder.
    Quinn D; Wigal S; Swanson J; Hirsch S; Ottolini Y; Dariani M; Roffman M; Zeldis J; Cooper T
    J Am Acad Child Adolesc Psychiatry; 2004 Nov; 43(11):1422-9. PubMed ID: 15502602
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Efficacy of Methylphenidate Hydrochloride Extended-Release Capsules (Aptensio XR™) in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder: A Phase III, Randomized, Double-Blind Study.
    Wigal SB; Nordbrock E; Adjei AL; Childress A; Kupper RJ; Greenhill L
    CNS Drugs; 2015 Apr; 29(4):331-40. PubMed ID: 25877989
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A single-dose, two-way crossover, bioequivalence study of dexmethylphenidate HCl with and without food in healthy subjects.
    Teo SK; Scheffler MR; Wu A; Stirling DI; Thomas SD; Stypinski D; Khetani VD
    J Clin Pharmacol; 2004 Feb; 44(2):173-8. PubMed ID: 14747426
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Association of salivary dehydroepiandrosterone levels and symptoms in patients with attention deficit hyperactivity disorder during six months of treatment with methylphenidate.
    Wang LJ; Hsiao CC; Huang YS; Chiang YL; Ree SC; Chen YC; Wu YW; Wu CC; Shang ZY; Chen CK
    Psychoneuroendocrinology; 2011 Sep; 36(8):1209-16. PubMed ID: 21411231
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Adverse response to methylphenidate in combination with valproic acid.
    Gara L; Roberts W
    J Child Adolesc Psychopharmacol; 2000; 10(1):39-43. PubMed ID: 10755581
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Efficacy and Safety of HLD200, Delayed-Release and Extended-Release Methylphenidate, in Children with Attention-Deficit/Hyperactivity Disorder.
    Pliszka SR; Wilens TE; Bostrom S; Arnold VK; Marraffino A; Cutler AJ; López FA; DeSousa NJ; Sallee FR; Incledon B; Newcorn JH
    J Child Adolesc Psychopharmacol; 2017 Aug; 27(6):474-482. PubMed ID: 29172680
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Single-Dose, Single-Period Pharmacokinetic Assessment of an Extended-Release Orally Disintegrating Tablet of Methylphenidate in Children and Adolescents with Attention-Deficit/Hyperactivity Disorder.
    Childress A; Newcorn J; Stark JG; McMahen R; Tengler M; Sikes C
    J Child Adolesc Psychopharmacol; 2016 Aug; 26(6):505-12. PubMed ID: 27228207
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Predictors of weight loss in children with attention deficit hyperactivity disorder treated with stimulant medication.
    Schertz M; Adesman AR; Alfieri NE; Bienkowski RS
    Pediatrics; 1996 Oct; 98(4 Pt 1):763-9. PubMed ID: 8885958
    [TBL] [Abstract][Full Text] [Related]  

  • 37. An open-label, randomized, active-controlled equivalent trial of osmotic release oral system methylphenidate in children with attention-deficit/hyperactivity disorder in Taiwan.
    Gau SS; Shen HY; Soong WT; Gau CS
    J Child Adolesc Psychopharmacol; 2006 Aug; 16(4):441-55. PubMed ID: 16958569
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacokinetics of methylphenidate in preschoolers with attention-deficit/hyperactivity disorder.
    Wigal SB; Gupta S; Greenhill L; Posner K; Lerner M; Steinhoff K; Wigal T; Kapelinski A; Martinez J; Modi NB; Stehli A; Swanson J
    J Child Adolesc Psychopharmacol; 2007 Apr; 17(2):153-64. PubMed ID: 17489710
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cytogenetic Effects of Chronic Methylphenidate Treatment and Chronic Social Stress in Adults with Attention-Deficit/Hyperactivity Disorder.
    Kittel-Schneider S; Spiegel S; Renner T; Romanos M; Reif A; Reichert S; Heupel J; Schnetzler L; Stopper H; Jacob C
    Pharmacopsychiatry; 2016 Jul; 49(4):146-54. PubMed ID: 26926233
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Does chirality matter? pharmacodynamics of enantiomers of methylphenidate in patients with attention-deficit/hyperactivity disorder.
    Quinn D
    J Clin Psychopharmacol; 2008 Jun; 28(3 Suppl 2):S62-6. PubMed ID: 18480679
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.